Corneal neovascularisation – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:23:20 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Corneal neovascularisation – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Testing Aganirsen Eye Drops in Patients with Corneal Blood Vessel Growth from Herpes Eye Disease Before Corneal Transplant Surgery https://clinicaltrials.eu/trial/testing-aganirsen-eye-drops-in-patients-with-corneal-blood-vessel-growth-from-herpes-eye-disease-before-corneal-transplant-surgery/ Wed, 29 Apr 2026 15:08:50 +0000 https://clinicaltrials.eu/trial/testing-aganirsen-eye-drops-in-patients-with-corneal-blood-vessel-growth-from-herpes-eye-disease-before-corneal-transplant-surgery/ This study examines a condition where the cornea, which is the clear front surface of the eye, has developed abnormal blood vessels and lymphatic vessels due to herpetic keratopathy, which is damage to the cornea caused by herpes virus infection. When the cornea becomes damaged by herpes infection, new blood vessels can grow into it where they normally should not be present, making the cornea less clear and affecting vision. People with this condition may need a corneal transplant, which is a surgical procedure to replace the damaged cornea with healthy donor tissue, but the presence of these abnormal vessels increases the risk that the transplant might not work well. The study will use several treatments including eye drops called Olisens that contain aganirsen, which is a substance designed to reduce the growth of these abnormal vessels. Some participants will receive placebo eye drops instead. Additionally, all participants will receive standard eye drops containing ofloxacin, which is an antibiotic to prevent infection, and dexamethasone sodium phosphate, which reduces inflammation. The study will also use a procedure called corneal crosslinking, which involves applying a special solution to the cornea and then exposing it to ultraviolet light to strengthen the cornea and help reduce the abnormal blood vessels.

The purpose of this study is to find out whether the antisense oligonucleotide eye drops work effectively in treating the abnormal blood vessels in the cornea when used together with the corneal crosslinking procedure. During the study, participants will receive either the active eye drops or placebo eye drops along with the other standard medications and will undergo the crosslinking procedure. The study will measure changes in the area of the cornea covered by abnormal blood vessels by taking standardized photographs of the eye using a special microscope called a slit lamp. The treatment period will last for several weeks, and participants will be followed for additional time to see how well the treatment works.

Throughout the study, various measurements will be taken to assess how well participants can see, including tests of visual sharpness both in normal conditions and with glare, which is bright light that can make seeing more difficult. The study will also evaluate how the condition and treatment affect quality of life related to vision and any eye pain experienced by participants. Other measurements will include eye pressure, the health of the eye surface, how well the cornea can sense touch, the thickness of the cornea, and detailed measurements of the blood vessels including their thickness and length. Safety will be monitored by examining the retina, which is the light-sensitive tissue at the back of the eye, and by tracking whether participants still need a corneal transplant after treatment.

]]> A Study of Aganirsen Eye Drops for Patients with Corneal Blood Vessel Growth in Aniridia-Associated Keratopathy https://clinicaltrials.eu/trial/a-study-of-aganirsen-eye-drops-for-patients-with-corneal-blood-vessel-growth-in-aniridia-associated-keratopathy/ Wed, 29 Apr 2026 15:08:16 +0000 https://clinicaltrials.eu/trial/a-study-of-aganirsen-eye-drops-for-patients-with-corneal-blood-vessel-growth-in-aniridia-associated-keratopathy/ This study examines a condition called Aniridia-Associated Keratopathy, which is a disease affecting the front clear part of the eye known as the cornea. In this condition, abnormal blood vessels grow into the cornea, which is normally clear and free of blood vessels. This abnormal growth of blood vessels is called Corneal Neovascularization and it occurs in people who have aniridia, a rare condition where part or all of the colored part of the eye is missing from birth. The treatment being tested is Olisens, which is also known by its scientific name aganirsen or code name GS101. This medication is an eye drop solution that works by blocking a specific substance in the body called IRS-1, which is involved in the formation of new blood vessels.

The purpose of this study is to test whether Olisens eye drops can stop or reduce the abnormal blood vessel growth in the cornea of people with Aniridia-Associated Keratopathy. The main goal is to measure if the treatment can decrease the area of the cornea that is covered by these unwanted blood vessels. During the study, participants will receive the eye drop treatment for up to 12 weeks, with a maximum daily dose of 0.52 milligrams. The study will track changes in the blood vessel coverage on the cornea using special photographs taken with a device called a slit lamp, which allows doctors to examine the eye in detail.

Throughout the study, several other measurements will be taken to understand how the treatment affects the eyes and the quality of life of participants. These include checking how well participants can see using special eye charts, measuring the pressure inside the eye, examining the surface of the eye for any damage, testing how sensitive the cornea is to touch, and measuring the thickness of the cornea. The study will also look at the characteristics of the blood vessels themselves, such as their thickness and length, and whether they shrink or come back after treatment. Additionally, participants will complete questionnaires about their vision-related quality of life and any eye pain they experience. The back part of the eye called the retina will also be examined to check for any unwanted effects of the treatment.

]]>